Table 2.
Antiviral activity of compounds against representative Enterovirus, Par-A reference and clinical isolates.
| Virus (strain) | Species | Cell line | EC50 (μM ± SD) |
|||
|---|---|---|---|---|---|---|
| Itraconazole | Posaconazole | Enviroxime | 25HC | |||
| EV-A71 (HuN13–1)a | Enterovirus-A | RD c | 3.02 ± 1.01 | 5.44 ± 0.82 | 0.47 ± 0.13 | 0.58 ± 0.19 |
| EV-A71 (AH-FY-04)a | Enterovirus-A | RD | 3.53 ± 1.38 | 0.49 ± 0.12 | 0.38 ± 0.13 | 0.42 ± 0.01 |
| CVB5 (Faulkner) | Enterovirus-B | HeLa d | 0.42 ± 0.19 | 1.82 ± 0.73 | 1.64 ± 0.46 | > 10 |
| E11 (Gregory) | Enterovirus-B | RD | 0.34 ± 0.04 | 1.01 ± 0.16 | 0.27 ± 0.12 | 4.69 ± 2.53 |
| Sabin 1 | Enterovirus-C | HeLa | 1.32 ± 0.41 | > 10 | 0.28 ± 0.04 | 1.61 ± 0.56 |
| CVA24v (KW83) | Enterovirus-C | HeLa | 1.31 ± 0.39 | 0.79 ± 0.24 | 0.75 ± 0.14 | 1.83 ± 0.31 |
| EV-D68 (14–18956)b | Enterovirus-D | RD | 3.15 ± 1.51 | 3.65 ± 1.73 | 0.18 ± 0.03 | 0.16 ± 0.08 |
| EV-D68 (14–18952)b | Enterovirus-D | RD | > 10 | 6.22 ± 1.91 | 1.45 ± 0.53 | 0.43 ± 0.02 |
|
| ||||||
| Par-A1 (Harris) | Parechovirus-A | Vero e | > 10 | > 10 | > 10 | > 10 |
| Par-A2 (Williamson) | Parechovirus-A | Vero | > 10 | > 10 | > 10 | > 10 |
| Par-A3 (US-WI-09) | Parechovirus-A | Vero | 1.17 ± 0.35 | 0.13 ± 0.01 | > 10 | > 10 |
| Par-A4 (T75–4077) | Parechovirus-A | Vero | > 10 | > 10 | > 10 | > 10 |
| Par-A5 (T75–15) | Parechovirus-A | Vero | > 10 | > 10 | > 10 | > 10 |
| Par-A6 (US-WI-10) | Parechovirus-A | Vero | > 10 | > 10 | > 10 | > 10 |
a
Isolate from China.
b
2014 outbreak strain, US-IL.
c
Human rhabdomyosarcoma cells.
d
Human epithelial cervical carcinoma cells.
e
African green monkey kidney cells.